These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 39258622)
41. Preservation of Anti-SARS-CoV-2 Neutralizing Antibodies in Breast Milk: Impact of Maternal COVID-19 Vaccination and Infection. Suteerojntrakool O; Mekangkul E; Maitreechit D; Khabuan S; Sodsai P; Hirankarn N; Thumbovorn R; Chomtho S Breastfeed Med; 2024 May; 19(5):340-348. PubMed ID: 38506333 [No Abstract] [Full Text] [Related]
42. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study. Kuloğlu ZE; El R; Guney-Esken G; Tok Y; Talay ZG; Barlas T; Kuskucu MA; Albayrak Ö; Doğan Ö; Yavuz SŞ; Midilli K; Ergönül Ö; Can F Allergy; 2022 Aug; 77(8):2459-2467. PubMed ID: 35437772 [TBL] [Abstract][Full Text] [Related]
43. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306 [TBL] [Abstract][Full Text] [Related]
44. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico. Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894 [TBL] [Abstract][Full Text] [Related]
45. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery. Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127 [TBL] [Abstract][Full Text] [Related]
46. Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination. Young BE; Seppo AE; Diaz N; Rosen-Carole C; Nowak-Wegrzyn A; Cruz Vasquez JM; Ferri-Huerta R; Nguyen-Contant P; Fitzgerald T; Sangster MY; Topham DJ; Järvinen KM JAMA Pediatr; 2022 Feb; 176(2):159-168. PubMed ID: 34757387 [TBL] [Abstract][Full Text] [Related]
47. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L Front Immunol; 2022; 13():829665. PubMed ID: 35154152 [TBL] [Abstract][Full Text] [Related]
48. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM Front Immunol; 2021; 12():747830. PubMed ID: 34858404 [TBL] [Abstract][Full Text] [Related]
49. Antibody responses post-booster COVID-19 vaccination: Insights from a single-center prospective cohort study. Dinç HÖ; Can G; Budak B; Daşdemir FO; Keskin E; Kirkoyun-Uysal H; Aydoğan O; Balkan II; Karaali R; Ergin S; Saltoğlu N; Kocazeybek B Diagn Microbiol Infect Dis; 2024 Oct; 110(2):116425. PubMed ID: 39098282 [TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298 [TBL] [Abstract][Full Text] [Related]
51. Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration. Mihaylova A; Lesichkova S; Baleva M; Nikolova-Vlahova M; Kundurzhiev T; Kolevski A; Naumova E J Med Virol; 2023 Jan; 95(1):e28360. PubMed ID: 36448089 [TBL] [Abstract][Full Text] [Related]
52. Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination. Sanada T; Honda T; Kohara M Vaccine; 2024 Aug; 42(21):126146. PubMed ID: 39033078 [TBL] [Abstract][Full Text] [Related]
53. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study. Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754 [TBL] [Abstract][Full Text] [Related]
54. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958 [TBL] [Abstract][Full Text] [Related]
56. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19]. Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968 [TBL] [Abstract][Full Text] [Related]
57. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children. Zhong Y; Kang AYH; Tay CJX; Li HE; Elyana N; Tan CW; Yap WC; Lim JME; Le Bert N; Chan KR; Ong EZ; Low JG; Shek LP; Tham EH; Ooi EE Nat Med; 2024 May; 30(5):1373-1383. PubMed ID: 38689059 [TBL] [Abstract][Full Text] [Related]
58. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. Demirbakan H; Koçer I; Erdoğan M; Bayram A Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127 [TBL] [Abstract][Full Text] [Related]
59. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines. Alroqi F; Barhoumi T; Masuadi E; Nogoud M; Aljedaie M; Abu-Jaffal AS; Bokhamseen M; Saud M; Hakami M; Arabi YM; Nasr A J Infect Public Health; 2024 Apr; 17(4):704-711. PubMed ID: 38479067 [TBL] [Abstract][Full Text] [Related]
60. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]